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Abstract
Acromegaly is characterized by autonomous growth hormone (GH) secretion from the 
pituitary somatotroph adenoma and increased levels of serum insulin-like growth factor 
I (IGF-I). These conditions are associated with increased morbidity and mortality due 
to metabolic conditions, cardiovascular diseases, and malignant neoplasms. Among 
neoplasms, while colorectal neoplasms are a well-known comorbidity in patients with 
acromegaly, the prevalence of colorectal benign or malignant tumors varies among stud-
ies. Although several underlying mechanisms have been proposed, recent studies have 
unveiled new insights into tumorigenesis. This review focused on the epidemiological 
studies of colorectal neoplasm in acromegaly and recent advances in the elucidation of 
the underlying mechanisms.
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1. Introduction
Acromegaly is characterized by excess levels of insulin-like growth factor I (IGF-I) derived 
from autonomous growth hormone (GH) secretion from the pituitary somatotroph adenoma, 
which results in acral enlargement, coarse facial features, and visceromegaly [1, 2]. Even 
worse, acromegalic patients exhibit a shorter life span than healthy subjects owing to various 
comorbidities such as diabetes; hypertension; and cardiovascular, cerebrovascular, and respi-
ratory diseases [1]. Malignant neoplasms in several organs including the thyroid, breast, pros-
tate, pancreas, and digestive tract are also widely recognized as representative complications 
[1, 3, 4]. Even among those, patients with acromegaly are well known to have a significantly 
higher prevalence of colon neoplasms than the general population. Recent evidence suggests 
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that even benign neoplasms such as adenoma and hyperplasia may have the potential to 
develop into malignant adenocarcinoma, which potentially affects the prognosis of acrome-
galic patients [5–7]. Recent guidelines recommend that while acromegalic patients are neces-
sary to undergo colonoscopy regularly, they often face difficulties throughout colonoscopy 
intubation owing to distinctive features of acromegaly such as elongation of the colon [8]. 
Recently, the molecular mechanism behind colon tumorigenesis associated with the GH-IGF-I 
excess has been elucidated. In this chapter, we review the epidemiological evidence, protocol 
of follow-up colonoscopy, and underlying mechanism of GH/IGF-I-associated colon tumori-
genesis in patients with acromegaly.
2. Epidemiology in colorectal neoplasms in acromegaly
Klein et al. first demonstrated an increased prevalence of colon polyps in patients with acro-
megaly in 1982, reporting a prevalence of colorectal adenomatous polyps of approximately 
30% in 17 patients with acromegaly [9]. Several subsequent reports also showed that colonic 
neoplasms were more frequently observed in 47% of patients with acromegaly, compared 
to the control with colonic lesions in 40% of asymptomatic males >50 years [10]. A cohort 
study identified 1041 male patients as having acromegaly from over 4 million men from the 
database of the United States Veterans Administration, which revealed a prevalence of acro-
megaly to be 277 cases/million [11]. In this study, 13 acromegalic patients had colonic cancer, 
which indicates a significantly higher prevalence than in the control group (SIR: 3.1; 95% 
CI 1.7–5.1) [11]. The UK registry of acromegaly diagnosed 16 patients as having colorectal 
cancer from a total of 1239 patients with acromegaly. Although this study did not show any 
significant change in the frequency of colorectal carcinoma compared to healthy subjects, the 
mortality rate of colon cancer was higher even though the overall mortality rate due to cancer 
was not increased [4]. An investigation of the incidence of cancer in 1643 hospitalized acro-
megalic patients in North Europe was performed, and the estimated standardized incidence 
ratio (SIR) was 2.6 (95% confidence interval [CI] 1.6–3.8) for overall colorectal cancer and 2.5 
(95% CI 1.3–4.2) for rectal carcinoma [12]. Terzolo et al. performed colonoscopy to screen for 
colorectal tumors in 235 patients with acromegaly and compared the prevalence of colorectal 
tumors in this cohort with the prevalence in a control population who had no past and family 
history of colonic disease. Patients with acromegaly exhibited a higher prevalence of colon 
adenomas (acromegaly; 23.4% vs. control; 14.6%; P = 0.001), hyperplastic polyps (19.1% vs. 
9.4%; P = 0.003), and cancer (4.3% vs. 0.9%; P = 0.036) [13]. The risk factor for colon cancer in 
acromegaly was young age, whereas there was no association between the prevalence of colon 
neoplasms and serum IGF-1 levels or disease duration [13]. Delhougne et al. reported similar 
results of acromegalic patients showing an increased prevalence of adenomatous (22.3% vs. 
8%; P = 0.0024) and hyperplastic polyps (24.3% vs. 4.4%; P < 0.001) compared to a control 
group [14]. In particular, younger people (younger than 55 years old) and men had a higher 
prevalence of adenomatous polyp than those in the control group (20.3% vs. 3.0%; P < 0.0026) 
[14]. Our recent study revealed that 57 Japanese acromegalic patients also exhibited a higher 
prevalence of colon adenomas (31.6% vs. 2.5%; P < 0.0001) and hyperplastic polyps (38.6% 
vs. 6.7%; P < 0.0001) than the historical control group with irritable bowel syndrome [15]. 
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Furthermore, colon cancer in patients with acromegaly exhibited an increased odds ratio of 
14.5 (95% CI 5.8–23.3) compared to that in the general Japanese population [15].
Thus, numerous studies documented evidence regarding risk of colorectal tumors in acro-
megalic patients, and several meta-analyses have demonstrated an increased prevalence 
of colorectal tumors including benign polyps and carcinomas. A German review meta-
analyzed 9 eligible papers with strict inclusion criteria from 106 studies. As benign polyps, 
the pooled ORs with 95% CI of hyperplastic polyps and colon adenomas were 3.7 (95% 
CI; 2.6–5.3) and 2.5 (95% CI; 1.9–3.4), respectively. In terms of colon cancer, the pooled OR 
with 95% CI was 4.4 (1.5–12.4) [16]. The second study meta-analyzed 14 papers to determine 
the incidence of colorectal cancer [17]. After exclusion criteria was <10 expected cases, stan-
dardized incidence ratios (SIRs) were obtained from eight studies and the pooled SIR was 
2.6 (95% CI; 1.7–4.0), which demonstrated an increased prevalence of colorectal cancer [18]. 
While the prevalence of colorectal cancer in female was significantly increased (SIR 1.86; 
95% CI, 1.06–3.28 P = 0.03), male patients had no change (SIR 1.44; 95% CI, 0.72–2.88 P = 0.31) 
[17]. An analysis of patients with acromegaly including male and female patients revealed 
that the SIR of colorectal cancer with 95% CI was significantly elevated (SIR 1.67; 95% CI, 
1.07–2.58, P = 0.022) [17]. Taken together, these meta-analyses demonstrated an increased 
risk of colorectal cancer in patients with acromegaly. There was a large variance in SIRs 
among studies from 1.4 [4] to 18.2 [3] and the difference in SIRs was observed depends 
on single center trials (SIR 7.3) and multicenter or population-based trials (SIR 2.0 and 2.2, 
respectively). In addition, two meta-analyses demonstrated that Japanese cohorts exhibited 
obviously higher prevalence of colorectal cancer in acromegalic patients than in other coun-
tries, suggesting that there may be an ethnic difference [16, 18].
3. Follow-up colonoscopy based on guidelines
Although some studies described the frequency of colonoscopy for the follow-up in patients 
with acromegaly, there is still controversy on the appropriate follow-up [13, 19, 20]. The 
guidelines in 2002 recommended that colonoscopy should be performed every 3–5 years 
considering the past history of colon neoplasms and family history [21]. The next revision 
in 2009 suggested that colonoscopy should be performed at least once upon diagnosis in all 
patients with acromegaly. If colon polyps were detected in patients with acromegaly at the 
first screening, they should be carefully followed up based on the guidelines of screening 
and surveillance for general colorectal cancer [22–24]. However, several groups still appealed 
the importance of repeated colonoscopy on a regular basis for acromegalic patients [25–27]. 
Dworakowska et al. reported that patients who were diagnosed as having adenomatous 
polyp at first screening had a higher risk of developing a new lesion at the subsequent follow-
up colonoscopy. Additionally, patients with poor IGF-I control had a 7.5-fold higher risk of a 
subsequent adenoma even if patients had a normal colon at the first screening [20].
The British Society of Gastroenterology and the Association of Coloproctology for Great 
Britain and Ireland in 2010 classified acromegalic patients as having a moderate to high 
risk of colorectal cancer on the update of the 2002 guidance, which suggested performing 
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colonoscopy screening in those 40 years of age or older on a regular basis [28]. The frequency 
of repeat colonoscopy should be modified depending on the conditions of the initial screening 
and the activity of acromegaly. If the initial screening test showed negative results and IGF-I 
level was within normal range, the next colonoscopy will be scheduled 5–10 years later. When 
adenomatous polyps were detected at initial screening or higher IGF-I levels were noted, 
follow-up colonoscopy should be performed every 3 years [28]. The medical guidelines of 
the American Association of Clinical Endocrinologists (2011) and the Acromegaly Consensus 
Group (2013) state a similar recommendation that acromegalic patients should undergo initial 
colonoscopy at the time of diagnosis. If persistently elevated IGF-I level, abnormal findings 
by colonoscopy, or a family history of colon cancer is noted, follow-up colonoscopy should be 
performed more frequently. If not, a follow-up colonoscopy should be recommended every 
10 years [29, 30].
Although current recommendations for surveillance colonoscopy in acromegaly may differ 
slightly among each study, collectively, it is deemed necessary to perform follow-up colo-
noscopy for cases with poor control of IGF-I and adenomatous polyps at least every 5 years 
according to five independent statements [20, 28, 29, 31]. Although an updated consensus 
from the Acromegaly Consensus Group in 2019 still recommends screening by colonoscopy 
at the time of diagnosis, they toned down the recommendation in terms of follow-up colo-
noscopy on a regular basis because there is no evidence linking screening frequency to colon 
cancer mortality rates [32, 33]. As acromegalic patients live longer than before owing to the 
improvement of biochemical control by advances in the treatment strategy, aging seems to 
be a more reliable indicator of cancer in patients with acromegaly than GH/IGF-I excess [34].
4. Underlying mechanism of colon neoplasm in acromegaly
4.1. GH signal
Secreted GH interacts with the GH receptor (GHR) that belongs to the class I cytokine recep-
tor family, which is mainly expressed in the liver, fat, and muscle [35]. Consequently, phos-
phorylated GHR induces janus kinase 2 (JAK2) phosphorylation, which results in tyrosine 
phosphorylation of STAT5 (signal transducer and activator of transcription 5). STAT5 is the 
physiologically essential transcription factor for GH-dependent body growth, lipid metabo-
lism, and sex-specific gene expression [36]. Recent studies have revealed that STAT5 plays 
an important role in tumorigenesis, especially cell proliferation and exertion of the anti-
apoptotic property [37]. The phosphorylated STAT5 is associated with the development of 
malignant neoplasms including malignant prostate neoplasms, malignant breast neoplasms, 
and leukemia [37–39]. In colorectal cancer, the expression level of STAT5B is higher than in the 
normal colon tissue, and also correlates with the TNM stage [40]. Furthermore, phosphory-
lated STAT5 in colon adenocarcinomas is associated with a poor prognosis [41]. The phos-
phorylation of STAT5 is suppressed by suppressor of cytokine signaling-2 (SOCS2) in the GH 
signaling pathway [42]. A previous paper reported that SOCS2-knockout exhibited the devel-
opment of hyperplastic mucosa and polyps in bovine GH-transgenic mice [43] Furthermore, 
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d3GHR polymorphism caused the signaling enhancement, which resulted in increasing the 
risk of colon adenoma regardless of circulating IGF-I concentration compared to intact GHR 
in acromegalic patients [44]. Recently, we reported that the GH area under the curve in the 
oral glucose tolerance test exhibited higher prevalence in colon cancer patients than in colonic 
benign tumor patients [15]. These data suggest the significance of excessive GH signaling in 
the development of epithelium-adenoma-carcinoma, independent of IGF-I signaling [45].
4.2. IGF-I signal
Bowel enlargement in acromegalic patients is observed associated with accumulative exces-
sive GH and IGF-I [46–48]. Enhanced proliferation of colonic epithelial cells and reduced 
apoptosis of the colonic mucosa were observed in patients with acromegaly [47, 49]. 
Interestingly, an increased proliferation rate of colonic epithelium cells was correlated with 
circulating IGF1 levels [50]. IGF-I receptor knockout mice exhibited a decreased cell prolif-
eration and increased apoptosis [1]. The IGF-I/IGF-IR system also plays an important role 
in the promotion of cell adhesion, migration, and tumor microenvironment including the 
angiogenesis in the tumor [51]. The IGF-IR mRNA expression level in the colon cancer tissue 
was associated with paracrine/autocrine effects [1]. Even in those with normal IGF-I levels, 
there was a positive association between circulating IGF-I levels and the risk of colorectal 
cancer in a meta-analysis of 19 epidemiological studies [52]. However, several previous stud-
ies suggested that the classification based on the type of colorectal neoplasms or with/without 
colorectal neoplasms did not correlate with serum IGF-I levels [13, 15, 53, 54]. Taken together, 
elevated levels of serum IGF-I may also involve colorectal tumorigenesis, but it still needs 
further investigation.
4.3. Local GH action in the colon
In terms of direct action of GH as a novel insight, it has recently been reported that locally 
expressed GH in the colon is a precursor to colon cancer. Excessive GH leads to cell survival 
with downregulation of tumor suppressor genes such as p53 and APC, which results in neo-
plastic colon growth [55]. GH suppressed DNA damage response (DDR) by inhibiting phos-
phorylated ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (Chk2), and p53. They 
also elucidated that GH significantly increased unrepaired DNA damage in colon epithelial 
cells, and colon cancer cell lines of xenografted mice with GH overexpression exhibited more 
metastases compared to colon cancer cell lines of control mice [56], and these mechanisms 
were observed independent of IGF-I action [57].
5. Underlying mechanism of hyperplastic polyp in acromegaly
As mentioned above, various mechanisms are involved in tumorigenesis of colorectal neo-
plasms. These mechanisms can account for the tumorigenesis of colorectal adenomatous 
polyps or adenocarcinomas, but not hyperplastic polyps. As a noteworthy fact, hyperplastic 
polyps are basically considered as benign neoplasms, while colorectal adenoma is widely 
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recognized as pre-malignant conditions based on the presence of the adenoma-carcinoma 
sequence. Indeed, hyperplastic polyps are described by a superficial serrated architecture and 
variably elongated crypts with proliferation confined to the lower portion of the crypt [58]. 
However, k-ras or BRAF mutations and microsatellite instability, which cause the malignant 
colorectal tumors, are detected in hyperplastic polyps [6]. In this aspect, hyperplastic polyps 
may need to be carefully diagnosed with histological examination in acromegaly. Acromegalic 
patients exhibited accelerated mucosal proliferation in the colon tissue compared to normal 
subjects [47, 59], which might involve in an increased prevalence of hyperplastic polyps. 
Further investigation is needed to elucidate the potential risk and underlying mechanism of 
the development of hyperplastic polyps in acromegaly.
6. Conclusion
Colorectal neoplasm, especially adenocarcinoma, is a life-threatening comorbidity of acro-
megaly. Accumulating data clearly demonstrate the increased prevalence of colorectal polyps 
and cancer in patients with acromegaly even among different races and countries. Although 
the appropriate follow-up protocol of colonoscopy remains controversial, different guidelines 
state that cases with poor control IGF-I and adenomatous polyps should be classified as hav-
ing a high risk of colon cancer. In terms of molecular mechanisms, both GH and IGF-I are 
implicated in colon cancer development.
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